Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 17053147
Dorrello NV, et al. (2006) S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 314, 467-71 17053147
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S473-p - Akt1 (human)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  brain cancer, glioblastoma, glioblastoma multiforme, glioma
Relevant cell lines - cell types - tissues:  T98G (glial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum no effect upon treatment-induced increase
SB203580 serum no effect upon treatment-induced increase
LY294002 serum inhibit treatment-induced increase
U0126 serum no effect upon treatment-induced increase

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  brain cancer, glioblastoma, glioblastoma multiforme, glioma
Relevant cell lines - cell types - tissues:  T98G (glial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum no effect upon treatment-induced increase
SB203580 serum no effect upon treatment-induced increase
LY294002 serum no effect upon treatment-induced increase
U0126 serum inhibit treatment-induced increase

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  brain cancer, glioblastoma, glioblastoma multiforme, glioma
Relevant cell lines - cell types - tissues:  T98G (glial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum no effect upon treatment-induced increase
SB203580 serum no effect upon treatment-induced increase
LY294002 serum no effect upon treatment-induced increase
U0126 serum inhibit treatment-induced increase

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  brain cancer, glioblastoma, glioblastoma multiforme, glioma
Relevant cell lines - cell types - tissues:  T98G (glial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum no effect upon treatment-induced increase
SB203580 serum no effect upon treatment-induced increase
LY294002 serum no effect upon treatment-induced increase
U0126 serum inhibit treatment-induced increase

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  brain cancer, glioblastoma, glioblastoma multiforme, glioma
Relevant cell lines - cell types - tissues:  T98G (glial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum no effect upon treatment-induced increase
SB203580 serum no effect upon treatment-induced increase
LY294002 serum no effect upon treatment-induced increase
U0126 serum inhibit treatment-induced increase

T412-p - p70S6K (human)
Modsite: NQVFLGFtyVAPsVL SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  brain cancer, glioblastoma, glioblastoma multiforme, glioma
Relevant cell lines - cell types - tissues:  T98G (glial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum inhibit treatment-induced increase
SB203580 serum no effect upon treatment-induced increase
LY294002 serum inhibit treatment-induced increase
U0126 serum no effect upon treatment-induced increase

S67-p - PDCD4 (human)
Modsite: kRRLRKNssRDsGrG SwissProt Entrez-Gene
Orthologous residues
PDCD4 (human): S67‑p, PDCD4 iso2 (human): S56‑p, PDCD4 (mouse): S67‑p, PDCD4 (rat): S67‑p, PDCD4 (cow): S67‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  brain cancer, glioblastoma, glioblastoma multiforme, glioma
Relevant cell lines - cell types - tissues:  293T (epithelial), T98G (glial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE p70S6K (human) phospho-antibody, modification site within consensus motif, transfection of inactive enzyme, pharmacological activator of upstream enzyme, transfection of constitutively active enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
Downstream Regulation
Effect of modification (function):  molecular association, regulation, protein degradation
Effect of modification (process):  cell cycle regulation, cell growth, altered, translation, altered
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
BTRC (human) Induces co-immunoprecipitation, pull-down assay

S71-p - PDCD4 (human)
Modsite: RKNssRDsGrGDsVs SwissProt Entrez-Gene
Orthologous residues
PDCD4 (human): S71‑p, PDCD4 iso2 (human): S60‑p, PDCD4 (mouse): S71‑p, PDCD4 (rat): S71‑p, PDCD4 (cow): S71‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  brain cancer, glioblastoma, glioblastoma multiforme, glioma
Relevant cell lines - cell types - tissues:  293T (epithelial), T98G (glial)
Cellular systems studied:  cell lines
Species studied:  human
Downstream Regulation
Effect of modification (function):  molecular association, regulation, protein degradation
Effect of modification (process):  cell cycle regulation, cell growth, altered, translation, altered
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
BTRC (human) Induces co-immunoprecipitation, pull-down assay

S76-p - PDCD4 (human)
Modsite: RDsGrGDsVsDsGsD SwissProt Entrez-Gene
Orthologous residues
PDCD4 (human): S76‑p, PDCD4 iso2 (human): S65‑p, PDCD4 (mouse): S76‑p, PDCD4 (rat): S76‑p, PDCD4 (cow): S76‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  brain cancer, glioblastoma, glioblastoma multiforme, glioma
Relevant cell lines - cell types - tissues:  293T (epithelial), T98G (glial)
Cellular systems studied:  cell lines
Species studied:  human
Downstream Regulation
Effect of modification (function):  molecular association, regulation, protein degradation
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
BTRC (human) Induces co-immunoprecipitation, pull-down assay

S235-p - S6 (human)
Modsite: IAKRRRLssLRAsts SwissProt Entrez-Gene
Orthologous residues
S6 (human): S235‑p, S6 (mouse): S235‑p, S6 (rat): S235‑p, S6 (fruit fly): A234‑p, S6 (cow): S235‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  brain cancer, glioblastoma, glioblastoma multiforme, glioma
Relevant cell lines - cell types - tissues:  T98G (glial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum inhibit treatment-induced increase
SB203580 serum no effect upon treatment-induced increase
LY294002 serum inhibit treatment-induced increase
U0126 serum no effect upon treatment-induced increase

S236-p - S6 (human)
Modsite: AKRRRLssLRAstsK SwissProt Entrez-Gene
Orthologous residues
S6 (human): S236‑p, S6 (mouse): S236‑p, S6 (rat): S236‑p, S6 (fruit fly): S235‑p, S6 (cow): S236‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  brain cancer, glioblastoma, glioblastoma multiforme, glioma
Relevant cell lines - cell types - tissues:  T98G (glial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum inhibit treatment-induced increase
SB203580 serum no effect upon treatment-induced increase
LY294002 serum inhibit treatment-induced increase
U0126 serum no effect upon treatment-induced increase